IBAB.BR Ion Beam Applications SA

Healthcare Health Care Equipment & Supplies Euronext Brussels
16.46 EUR
Close of Oct 29, 2026
9.84 17.72
Market cap
EUR 478M
P/E
20.1x
P/B
3.98x
ROE
31.2%
Dividend yield
1.49%
Fundamental score
2.3/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is IBAB.BR undervalued?

Graham number
Price16.46
Graham value8.73
Premium88.5%

IBAB.BR trades 88.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ion Beam Applications SA fundamental analysis

11 of 22 checks passed

ROE 2/2

High return on equity (31.2%), above 20%.

ROA 1/1

Return on assets (4.9%) is above the industry median (2.0%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (40.0%) is above the 5-year average (-16.7% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (40.0%) is above the industry median (10.1%).

Revenue Growth 2/2

Revenue grew 19.7% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (99.7%), up to 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 1/1

EBIT is 6.2x against interest expense, well covered.

PE vs Market 0/1

PE (20.1x) is above the market median (12.0x).

PE vs Industry 0/1

PE (20.1x) is above the industry median (16.1x).

PBV 0/1

Price to book (4.0x) is above the industry median (1.7x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 79.9, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (1.5%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 55.9%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Ion Beam Applications SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ion Beam Applications SA

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation …

Full company profile